Hepato Cellular Carcinoma
6
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
33%
2 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (6)
Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer
Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE
PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)
IIT2025-03-YANG-LIFT-HCC